According to a recent LinkedIn post from Brevel Ltd, the company and its Purallis™ chlorella ingredient have been featured in industry publication Nutrition Insight. The coverage is described as focusing on how Brevel is addressing long-standing supply and quality challenges in the chlorella market for nutraceutical applications.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights that Purallis™ is produced via an illuminated fermentation platform in fully controlled, sterile bioreactors, aiming to deliver ultra-pure chlorella free from heavy metals and contaminants. It also emphasizes year-round industrial-scale availability and nutritional attributes such as complete protein, antioxidants, and chlorophyll, targeting nutraceutical brands seeking reliable sourcing.
For investors, this media visibility in a specialized ingredients and nutraceuticals outlet suggests growing recognition of Brevel’s technology and product positioning within the functional ingredients supply chain. If the company can convert this attention into commercial agreements with nutraceutical brands, it could bolster revenue prospects and reinforce its competitive standing in the microalgae-based ingredient segment.